TY - JOUR
T1 - Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension
AU - Canzanello, Vincent J.
AU - Baranco-Pryor, Evelyn
AU - Rahbari-Oskoui, Frederic
AU - Schwartz, Gary L.
AU - Boerwinkle, Eric
AU - Turner, Stephen T.
AU - Chapman, Arlene B.
N1 - Funding Information:
acknowledgments: We gratefully acknowledge the biostatistical analyses of ZhiyingWang and the provision of candesartan by the astraZeneca company. This work was supported by the General Clinical Research Centers at Emory University (M01-RR00039) and Mayo Clinic, Rochester (M01-RR00585).This work was also supported by the Rochester Family Heart Study and US Public Health Service grant RO1 HL 53330 from the Division of Research Resources, National Institutes of Health; and funds from the Clinical Research Program, Mayo Foundation.
PY - 2008/1
Y1 - 2008/1
N2 - Background: Response to antihypertensive drugs varies widely among individuals. Methods: We studied characteristics that might be predictive of blood pressure (BP) response in 203 African-American and 236 non-Hispanic white subjects with essential hypertension treated with candesartan, 32 mg/day for 6 weeks, after a drug-free washout period of at least 4 weeks (baseline). Measurements at enrollment, baseline, and at the end of the treatment were incorporated into linear regression models to quantify their additive contributions to predicting response. Results: Enrollment measurements predictive of a greater response were non-Hispanic white ethnicity, female gender, the interaction between ethnicity and gender, and lower body weight. Of baseline measurements, higher BP and higher plasma renin activity (PRA) made additional contributions to predicting a greater response. Of the measurements made at the end of the study, only a larger increase in PRA from baseline contributed to predicting a greater response. The combined effects of all the identified predictors accounted for 39 and 33% of the interindividual variation in systolic and diastolic BP responses, respectively (P < 0.001 for both). Conclusions: These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB).
AB - Background: Response to antihypertensive drugs varies widely among individuals. Methods: We studied characteristics that might be predictive of blood pressure (BP) response in 203 African-American and 236 non-Hispanic white subjects with essential hypertension treated with candesartan, 32 mg/day for 6 weeks, after a drug-free washout period of at least 4 weeks (baseline). Measurements at enrollment, baseline, and at the end of the treatment were incorporated into linear regression models to quantify their additive contributions to predicting response. Results: Enrollment measurements predictive of a greater response were non-Hispanic white ethnicity, female gender, the interaction between ethnicity and gender, and lower body weight. Of baseline measurements, higher BP and higher plasma renin activity (PRA) made additional contributions to predicting a greater response. Of the measurements made at the end of the study, only a larger increase in PRA from baseline contributed to predicting a greater response. The combined effects of all the identified predictors accounted for 39 and 33% of the interindividual variation in systolic and diastolic BP responses, respectively (P < 0.001 for both). Conclusions: These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB).
UR - http://www.scopus.com/inward/record.url?scp=38349102205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349102205&partnerID=8YFLogxK
U2 - 10.1038/ajh.2007.24
DO - 10.1038/ajh.2007.24
M3 - Article
C2 - 18091745
AN - SCOPUS:38349102205
SN - 0895-7061
VL - 21
SP - 61
EP - 66
JO - American Journal of Hypertension
JF - American Journal of Hypertension
IS - 1
ER -